Free Trial Information
BioCentury | Aug 30, 2012
Distillery Techniques

Technology: Disease models

...mice and using the model to evaluate the effects of a brain-permeable HO-1 inhibitor from Osta Biotechnologies Inc....
Read More
BioCentury | May 14, 2012
Financial News

Osta Biotechnologies financial update

...its financial statements due to limited financial resources and a continuing difficulty raising additional capital. Osta Biotechnologies Inc....
Read More
BioCentury | Apr 9, 2012
Company News

Osta Biotechnologies cancer, neurology news

...In November, Osta raised C$150,000 ($145,305) in a unit offering (see BioCentury, Dec. 5, 2011). Osta Biotechnologies Inc....
Read More
BioCentury | Jan 5, 2012
Distillery Therapeutics

Indication: Infectious disease

...evaluating an HO-1 inhibitor in additional models of malaria-Salmonella co-infection. OB-24, an HO-1 inhibitor from Osta Biotechnologies Inc....
Read More
BioCentury | Dec 5, 2011
Financial News

Osta Biotechnologies completes private placement of units

Osta Biotechnologies Inc. (TSX-V:OBI), Dollard-des-Ormeaux, Quebec Business: Cancer, Neurology, Musculoskeletal Date completed: 11/18/11 Type: Private placement of units Raised: C$150,000 ($145,305) Units: 3 million Price: C$0.05 (unit) Shares after offering: 46.8 million Placement agent: Sherbrooke...
Read More
BioCentury | Aug 25, 2011
Distillery Therapeutics

Indication: Cancer

...with vehicle. Next steps include evaluating HMOX1 inhibitors in mouse models of FH mutant cancers. Osta Biotechnologies Inc.'s...
Read More
BioCentury | Jul 12, 2010
Clinical News

Osta Biotechnologies preclinical data

...OB-28 is a small molecule heme oxygenase decycling 1 ( HMOX1 ; HO-1 ) inhibitor. Osta Biotechnologies Inc....
Read More
BioCentury | Apr 12, 2010
Financial News

Osta Biotechnologies completes private placement of units

Osta Biotechnologies Inc. (TSX-V:OBI), Dollard-des-Ormeaux, Quebec Business: Cancer, Neurology, Musculoskeletal Date completed: 4/6/10 Type: Private placement of units Raised: C$504,000 (US$500,674) Units: 8.4 million Price: C$0.06 (unit) Shares after offering: 43.8 million Underwriter: Sherbrooke Street...
Read More
BioCentury | Feb 15, 2010
Financial News

Osta Biotechnologies proposes private placement of units

Osta Biotechnologies Inc. (TSX-V:OBI), Dollard-des-Ormeaux, Quebec Business: Cancer, Neurology, Musculoskeletal Date announced: 2/9/10 Type: Private placement of units To be raised: Up to C$2.5 million (US$2.3 million) Units: 17.9 million Price: C$0.14 (unit) Placement agent:...
Read More
Items per page:
1 - 9 of 9
BioCentury | Aug 30, 2012
Distillery Techniques

Technology: Disease models

...mice and using the model to evaluate the effects of a brain-permeable HO-1 inhibitor from Osta Biotechnologies Inc....
Read More
BioCentury | May 14, 2012
Financial News

Osta Biotechnologies financial update

...its financial statements due to limited financial resources and a continuing difficulty raising additional capital. Osta Biotechnologies Inc....
Read More
BioCentury | Apr 9, 2012
Company News

Osta Biotechnologies cancer, neurology news

...In November, Osta raised C$150,000 ($145,305) in a unit offering (see BioCentury, Dec. 5, 2011). Osta Biotechnologies Inc....
Read More
BioCentury | Jan 5, 2012
Distillery Therapeutics

Indication: Infectious disease

...evaluating an HO-1 inhibitor in additional models of malaria-Salmonella co-infection. OB-24, an HO-1 inhibitor from Osta Biotechnologies Inc....
Read More
BioCentury | Dec 5, 2011
Financial News

Osta Biotechnologies completes private placement of units

Osta Biotechnologies Inc. (TSX-V:OBI), Dollard-des-Ormeaux, Quebec Business: Cancer, Neurology, Musculoskeletal Date completed: 11/18/11 Type: Private placement of units Raised: C$150,000 ($145,305) Units: 3 million Price: C$0.05 (unit) Shares after offering: 46.8 million Placement agent: Sherbrooke...
Read More
BioCentury | Aug 25, 2011
Distillery Therapeutics

Indication: Cancer

...with vehicle. Next steps include evaluating HMOX1 inhibitors in mouse models of FH mutant cancers. Osta Biotechnologies Inc.'s...
Read More
BioCentury | Jul 12, 2010
Clinical News

Osta Biotechnologies preclinical data

...OB-28 is a small molecule heme oxygenase decycling 1 ( HMOX1 ; HO-1 ) inhibitor. Osta Biotechnologies Inc....
Read More
BioCentury | Apr 12, 2010
Financial News

Osta Biotechnologies completes private placement of units

Osta Biotechnologies Inc. (TSX-V:OBI), Dollard-des-Ormeaux, Quebec Business: Cancer, Neurology, Musculoskeletal Date completed: 4/6/10 Type: Private placement of units Raised: C$504,000 (US$500,674) Units: 8.4 million Price: C$0.06 (unit) Shares after offering: 43.8 million Underwriter: Sherbrooke Street...
Read More
BioCentury | Feb 15, 2010
Financial News

Osta Biotechnologies proposes private placement of units

Osta Biotechnologies Inc. (TSX-V:OBI), Dollard-des-Ormeaux, Quebec Business: Cancer, Neurology, Musculoskeletal Date announced: 2/9/10 Type: Private placement of units To be raised: Up to C$2.5 million (US$2.3 million) Units: 17.9 million Price: C$0.14 (unit) Placement agent:...
Read More
Items per page:
1 - 9 of 9